Tower Research Capital LLC TRC Acquires New Holdings in Eli Lilly And Co (NYSE:LLY)

Tower Research Capital LLC TRC acquired a new stake in shares of Eli Lilly And Co (NYSE:LLY) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 12,795 shares of the company’s stock, valued at approximately $1,431,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Bessemer Group Inc. boosted its holdings in shares of Eli Lilly And Co by 2,354.5% in the second quarter. Bessemer Group Inc. now owns 569,510 shares of the company’s stock valued at $63,096,000 after buying an additional 546,307 shares during the period. Cedar Capital LLC boosted its holdings in shares of Eli Lilly And Co by 17.5% in the second quarter. Cedar Capital LLC now owns 2,459 shares of the company’s stock valued at $272,000 after buying an additional 367 shares during the period. Assetmark Inc. boosted its holdings in shares of Eli Lilly And Co by 13.9% in the second quarter. Assetmark Inc. now owns 410,334 shares of the company’s stock valued at $45,461,000 after buying an additional 50,087 shares during the period. Haverford Trust Co. boosted its holdings in shares of Eli Lilly And Co by 60.3% in the second quarter. Haverford Trust Co. now owns 6,418 shares of the company’s stock valued at $711,000 after buying an additional 2,414 shares during the period. Finally, Naples Global Advisors LLC boosted its holdings in shares of Eli Lilly And Co by 1.1% in the second quarter. Naples Global Advisors LLC now owns 15,591 shares of the company’s stock valued at $1,727,000 after buying an additional 170 shares during the period. Hedge funds and other institutional investors own 77.37% of the company’s stock.

LLY traded down $0.38 during trading hours on Wednesday, hitting $112.79. 3,275,038 shares of the company’s stock were exchanged, compared to its average volume of 7,611,776. Eli Lilly And Co has a 1-year low of $101.36 and a 1-year high of $132.13. The stock’s 50-day moving average is $110.43 and its two-hundred day moving average is $112.61. The stock has a market cap of $109.00 billion, a price-to-earnings ratio of 20.32, a PEG ratio of 1.86 and a beta of 0.16. The company has a quick ratio of 0.88, a current ratio of 1.17 and a debt-to-equity ratio of 4.09.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.43 by $0.05. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The business had revenue of $5.48 billion during the quarter, compared to analysts’ expectations of $5.50 billion. During the same quarter in the prior year, the company posted $1.39 earnings per share. The firm’s revenue was up 3.2% on a year-over-year basis. On average, equities research analysts anticipate that Eli Lilly And Co will post 5.78 EPS for the current year.

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be issued a dividend of $0.645 per share. This represents a $2.58 annualized dividend and a yield of 2.29%. The ex-dividend date is Thursday, November 14th. Eli Lilly And Co’s payout ratio is 46.49%.

In other news, CFO Joshua L. Smiley purchased 929 shares of the company’s stock in a transaction on Friday, October 25th. The shares were purchased at an average cost of $107.59 per share, with a total value of $99,951.11. Following the completion of the transaction, the chief financial officer now owns 31,524 shares of the company’s stock, valued at approximately $3,391,667.16. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Jackson P. Tai purchased 1,861 shares of the company’s stock in a transaction on Thursday, October 24th. The shares were purchased at an average cost of $107.49 per share, for a total transaction of $200,038.89. Following the completion of the transaction, the director now directly owns 56,440 shares of the company’s stock, valued at approximately $6,066,735.60. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 8,405 shares of company stock valued at $909,004 and have sold 614,473 shares valued at $70,558,302. Corporate insiders own 0.11% of the company’s stock.

Several research firms have recently weighed in on LLY. UBS Group reduced their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. TheStreet upgraded shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Finally, Bank of America began coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. Six analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. Eli Lilly And Co presently has an average rating of “Buy” and a consensus price target of $130.03.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Read More: Consumer Price Index (CPI)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.